Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.

Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, Lu KH.

Gynecol Oncol. 2011 May 1;121(2):358-63. doi: 10.1016/j.ygyno.2010.12.354.

2.

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.

Sandhu SK, Yap TA, de Bono JS.

Eur J Cancer. 2010 Jan;46(1):9-20. doi: 10.1016/j.ejca.2009.10.021. Review.

PMID:
19926276
3.

Cancer statistics, 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006.

4.

BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.

Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit K, Robson ME.

J Clin Oncol. 2009 Jan 20;27(3):433-8. doi: 10.1200/JCO.2008.18.5546.

5.
7.

Resistance to therapy caused by intragenic deletion in BRCA2.

Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A.

Nature. 2008 Feb 28;451(7182):1111-5. doi: 10.1038/nature06548.

PMID:
18264088
8.

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.

Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA.

J Natl Cancer Inst. 2006 Dec 6;98(23):1694-706.

9.

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.

McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A.

Cancer Biol Ther. 2005 Sep;4(9):934-6.

PMID:
16251802
10.

BRCA2 germline mutations in familial pancreatic carcinoma.

Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, Campra D, Gr├╝tzmann R, Rehder H, Rothmund M, Schmiegel W, Neoptolemos JP, Bartsch DK.

J Natl Cancer Inst. 2003 Feb 5;95(3):214-21.

11.

Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL.

J Natl Cancer Inst. 2002 Sep 18;94(18):1365-72.

12.

Cancer risks in BRCA2 mutation carriers.

Breast Cancer Linkage Consortium..

J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6.

Items per page

Supplemental Content

Support Center